Feasibility study - a mean for multi-faceted assessment of the idea of establishing radioisotope production and introducing new radiopharmaceuticals into clinical practice

Kolevska, Katerina and Cocevska, Maja and Atanasova, Marija and Velickovska, Maja and Jolevski, Filip and Janevik-Ivanovska, Emilija and Petrova, Guenka and Ugrinska, Ana and Angelovska, Bistra (2024) Feasibility study - a mean for multi-faceted assessment of the idea of establishing radioisotope production and introducing new radiopharmaceuticals into clinical practice. In: 11th Balkan Congress of Nuclear Medicine, 30 May - 02 Jun 2024, Skopje, North Macedonia.

[thumbnail of FINAL PROGRAMME BCNM'24.pdf] Text
FINAL PROGRAMME BCNM'24.pdf

Download (19MB)
[thumbnail of 04 Kolevska Katerina.pdf] Text
04 Kolevska Katerina.pdf

Download (1MB)

Abstract

With the aim of obtaining an objective insight into the idea of establishing the production of zirconium-89 radioisotope and introducing 89Zr-radiopharmaceuticals into clinical practice, a feasibility study was prepared.
This study was originally designed and covers several aspects. The preliminary analysis comprised a review of the application of 89Zr-radiopharmaceuticals in clinical trials and a statistical data review regarding malignant diseases. The market research included searches on the distribution of medical cyclotrons and production sites of zirconium-89 radioisotope in Europe. The technical feasibility determination was based on the analysis of the technical capacities of the production site – University Institute of Positron Emission Tomography (UI PET), in terms of space and equipment necessary for producing zirconium-89 radioisotope. The economic feasibility estimation comprehended financial and pharmacoeconomic analysis. The production process was simulated and a cost analysis was used to calculate the cost of production of zirconium-89 radioisotope and 89Zr-trastuzumab radiopharmaceutical. A cost-benefit analysis was conducted to assess the cost-benefit ratio of either testing patients with 89Zr-trastuzumab PET/CT or biopsy as the comparison alternatives.
By the evaluation of the data from all conducted analyses, favourable and unfavourable factors and circumstances were identified, indicating some challenges but also opportunities towards better cancer management and research development.

Item Type: Conference or Workshop Item (Speech)
Subjects: Medical and Health Sciences > Other medical sciences
Divisions: Faculty of Medical Science
Depositing User: Maja Cocevska
Date Deposited: 01 Jul 2024 07:27
Last Modified: 01 Jul 2024 07:27
URI: https://eprints.ugd.edu.mk/id/eprint/34356

Actions (login required)

View Item View Item